Solid Biosciences (SLDB) Competitors

Erasca (NASDAQ:ERAS) and Solid Biosciences (NASDAQ:SLDB) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, community ranking, risk, valuation, profitability, earnings, analyst recommendations and institutional ownership.

Does the MarketBeat Community favor ERAS or SLDB?

Solid Biosciences received 245 more outperform votes than Erasca when rated by MarketBeat users. However, 70.59% of users gave Erasca an outperform vote while only 68.80% of users gave Solid Biosciences an outperform vote.

Company	Underperform	Outperform
Erasca	Outperform Votes 24 70.59%	Underperform Votes 10 29.41%
Solid Biosciences	Outperform Votes 269 68.80%	Underperform Votes 122 31.20%

Do insiders and institutionals hold more shares of ERAS or SLDB?

67.8% of Erasca shares are held by institutional investors. Comparatively, 81.5% of Solid Biosciences shares are held by institutional investors. 21.5% of Erasca shares are held by company insiders. Comparatively, 13.6% of Solid Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Is ERAS or SLDB more profitable?

Erasca's return on equity of -42.26% beat Solid Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Erasca	N/A	-42.26%	-34.97%
Solid Biosciences	N/A	-58.75%	-47.84%

Do analysts prefer ERAS or SLDB?

Erasca presently has a consensus price target of $5.90, suggesting a potential upside of 135.06%. Solid Biosciences has a consensus price target of $15.22, suggesting a potential upside of 266.80%. Given Solid Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Solid Biosciences is more favorable than Erasca.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Erasca	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80
Solid Biosciences	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	4 Strong Buy rating(s)	3.33

Which has stronger valuation & earnings, ERAS or SLDB?

Solid Biosciences has higher revenue and earnings than Erasca. Erasca is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Erasca	N/A	N/A	-$125.04M	-$0.83	-3.02
Solid Biosciences	$8.09M	20.50	-$96.01M	-$3.04	-1.37

Which has more risk and volatility, ERAS or SLDB?

Erasca has a beta of 1.2, indicating that its share price is 20% more volatile than the S&P 500. Comparatively, Solid Biosciences has a beta of 2.01, indicating that its share price is 101% more volatile than the S&P 500.

Does the media refer more to ERAS or SLDB?

In the previous week, Solid Biosciences had 8 more articles in the media than Erasca. MarketBeat recorded 11 mentions for Solid Biosciences and 3 mentions for Erasca. Erasca's average media sentiment score of 1.54 beat Solid Biosciences' score of 0.99 indicating that Erasca is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Erasca	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Solid Biosciences	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Solid Biosciences beats Erasca on 11 of the 17 factors compared between the two stocks.